Merck KGaA sets up 40 millon euro venture capital fund
Merck KGaA has unveiled plans for a “strategic, corporate venture capital fund” which will invest in emerging biotechnology companies.
Read MoreAuthor: Kevin Grogan
Proactive patients will transform healthcare – EIU report
A new report claims that patient involvement will become more crucial for controlling healthcare costs and improving standards.
Read MoreEuropean biosimilars market set for steady growth
A new report has claimed that “despite the initial regulatory hiccups”, the number of biosimilars that make it to the European market is set to increase gradually.
Read MoreShire withdraws more batches of Daytrana patches in USA
Shire has announced yet another “non-safety-related voluntary market withdrawal” in the USA of a number of its Daytrana attention deficit hyperactivity disorder patches.
Read MoreForest’s Lexapro approved for adolescents with MDD
Weeks after being accused of illegally marketing Lexapro for children, Forest Laboratories has received approval from US regulators to sell the antidepressant to teenagers.
Read More- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
